Orpyx® Medical Technologies Secures $7.6M in Series A Funding

Orpyx® Medical Technologies an innovator in digital health therapeutics to prevent diabetic foot complications, today announced the close of a $7.6M Series A investment round. Paddock Capital Inc. led the investment round with participation from existing and new investors, including Aphelion Capital, Thin Air Labs, InterGen Capital, Relentless Venture Fund, ICM Asset Management, Anges Québec, Picante Capital Corp. and Viewpoint Group. The investment brings Orpyx’s total funding since inception of the company to $18.5M and will help the company expand its North American commercialization efforts as well as broaden and accelerate technology development. Cory Paddock, co-founder and Managing Director of Paddock Capital Inc, will join the Board of Directors.

“Orpyx’s product offering is well-timed with the increasing demand for telemedicine solutions that help serve people with diabetes,” said Cory Paddock, Managing Director of Paddock Capital. “It is estimated $176B is spent in the US alone on diabetes care, of which $60B is directly related to lower limb care. Orpyx is on the forefront of technology that enables preventative care that will not only prevent diabetic foot ulcers (DFUs) from occurring but will also decrease costs for the health system.”

The Series A financing builds on an exceptional year for Orpyx, which has included the launch of their flagship product line, Orpyx® SI Sensory Insoles, the only sensory insole with telemedicine capabilities that provides patients and their healthcare provider real-world feedback to help prevent diabetic foot and other neuropathy-related ulcers. The launch was preceded by the publication of a first-of-its-kind, randomized control trial that when compared to standard of care demonstrated up to an 86% reduction in DFU recurrence in people with a previous DFU and diabetic peripheral neuropathy, which often results in a lack of protective pain sensation.

“For the first time, we can provide sensory feedback through a simple user interface to provide real-time physiological data to the wearer.  Previously, this type of accuracy was only available in a research setting, but now it can be used in the real-world so patients and healthcare providers can collaborate to help prevent DFUs. Studies show that patients with DFUs were seen in outpatient facilities 14 times per year and hospitalized approximately 1.5 times per year. Our goal is to advance current standard of care to improve patient quality of life and mobility, while substantially decreasing healthcare costs,” stated Dr. Breanne Everett, Orpyx CEO and co-inventor.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy